Published in Proc Natl Acad Sci U S A on April 28, 2003
Study Of PHarmacogenetics in Ethnically Diverse Populations (SOPHIE Study) (SOPHIE) | NCT00187668
Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci U S A (2003) 5.77
Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest (2007) 4.47
Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev (2010) 2.97
Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther (2007) 2.80
Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res (2006) 2.37
cis-Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects. Proc Natl Acad Sci U S A (2008) 1.62
Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum. Diabetes Care (2013) 1.56
Human serotonin transporter variants display altered sensitivity to protein kinase G and p38 mitogen-activated protein kinase. Proc Natl Acad Sci U S A (2005) 1.53
Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes (2009) 1.34
Comparison of human solute carriers. Protein Sci (2010) 1.29
Structure-based discovery of prescription drugs that interact with the norepinephrine transporter, NET. Proc Natl Acad Sci U S A (2011) 1.29
Functional genomics of membrane transporters in human populations. Genome Res (2005) 1.27
Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function. Pharmacogenomics J (2009) 1.18
Systems-based approaches to cardiovascular disease. Nat Rev Cardiol (2012) 1.04
The pharmacogenomics of membrane transporters project: research at the interface of genomics and transporter pharmacology. Clin Pharmacol Ther (2009) 1.01
Pharmacophore modelling of stereoselective binding to the human organic cation transporter (hOCT1). Br J Pharmacol (2007) 1.00
Regulation of organic cation transport. Pflugers Arch (2004) 0.98
An update on the pharmacogenomics of metformin: progress, problems and potential. Pharmacogenomics (2014) 0.97
The use of orthologous sequences to predict the impact of amino acid substitutions on protein function. PLoS Genet (2010) 0.97
Molecular modeling and ligand docking for solute carrier (SLC) transporters. Curr Top Med Chem (2013) 0.95
Hepatocyte nuclear factor 1 regulates the expression of the organic cation transporter 1 via binding to an evolutionary conserved region in intron 1 of the OCT1 gene. J Pharmacol Exp Ther (2013) 0.91
Pharmacogenetics of metformin response: a step in the path toward personalized medicine. J Clin Invest (2007) 0.90
PharmGKB summary: tramadol pathway. Pharmacogenet Genomics (2014) 0.89
Role of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacology. Biomed Res Int (2013) 0.87
OCT1 and imatinib transport in CML: is it clinically relevant? Leukemia (2015) 0.84
Genetic analysis of OCT1 gene polymorphisms in an Indian population. Indian J Hum Genet (2011) 0.82
The pharmacogenetics of imanitib. Genome Med (2010) 0.82
Influences of organic cation transporter polymorphisms on the population pharmacokinetics of metformin in healthy subjects. AAPS J (2013) 0.81
Variation in genes controlling warfarin disposition and response in American Indian and Alaska Native people: CYP2C9, VKORC1, CYP4F2, CYP4F11, GGCX. Pharmacogenet Genomics (2015) 0.81
Genetic polymorphisms of OCT-1 confer susceptibility to severe progression of primary biliary cirrhosis in Japanese patients. J Gastroenterol (2013) 0.81
Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug-drug interactions. Pharmacogenomics J (2015) 0.80
Human organic cation transporter 1 (hOCT1) as a mediator of bendamustine uptake and cytotoxicity in chronic lymphocytic leukemia (CLL) cells. Pharmacogenomics J (2015) 0.80
Genetic variation of COLEC10 and COLEC11 and association with serum levels of collectin liver 1 (CL-L1) and collectin kidney 1 (CL-K1). PLoS One (2015) 0.79
Expression of mRNA transcripts encoding membrane transporters detected with whole transcriptome sequencing of human brain and liver. Pharmacogenet Genomics (2013) 0.79
Pharmacogenomic implications of the evolutionary history of infectious diseases in Africa. Pharmacogenomics J (2016) 0.78
The pharmacogenetics of metformin. Diabetologia (2017) 0.77
Stereoselective binding of chiral ligands to single nucleotide polymorphisms of the human organic cation transporter-1 determined using cellular membrane affinity chromatography. Anal Biochem (2010) 0.77
Nucleoside transporters and human organic cation transporter 1 determine the cellular handling of DNA-methyltransferase inhibitors. Br J Pharmacol (2014) 0.77
Genetic polymorphisms and haplotypes of the organic cation transporter 1 gene (SLC22A1) in the Xhosa population of South Africa. Genet Mol Biol (2014) 0.76
Role of Human Organic Cation Transporter 1 (hOCT1) Polymorphisms in Lamivudine (3TC) Uptake and Drug-Drug Interactions. Front Pharmacol (2016) 0.75
Global genetic analyses reveal strong inter-ethnic variability in the loss of activity of the organic cation transporter OCT1. Genome Med (2015) 0.75
Uptake of pramipexole by human organic cation transporters. Mol Pharm (2010) 0.75
A novel approach using C. elegans DNA damage-induced apoptosis to characterize the dynamics of uptake transporters for therapeutic drug discoveries. Sci Rep (2016) 0.75
Characterization of Disease-Associated Mutations in Human Transmembrane Proteins. PLoS One (2016) 0.75
Ischemia/Reperfusion-inducible protein modulates the function of organic cation transporter 1 and multidrug and toxin extrusion 1. Mol Pharm (2013) 0.75
PharmGKB summary: very important pharmacogene information for SLC22A1. Pharmacogenet Genomics (2014) 0.75
Amino acid substitution matrices from protein blocks. Proc Natl Acad Sci U S A (1992) 61.33
A new statistical method for haplotype reconstruction from population data. Am J Hum Genet (2001) 59.30
Predicting deleterious amino acid substitutions. Genome Res (2001) 28.95
Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet (1999) 24.24
Amino acid difference formula to help explain protein evolution. Science (1974) 15.19
Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science (1983) 9.41
Pharmacogenomics: translating functional genomics into rational therapeutics. Science (1999) 8.25
Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci U S A (2003) 5.77
A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet (1998) 3.33
A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis. Nat Genet (1998) 3.09
Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther (2002) 2.36
Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol (1997) 1.91
Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene. Mol Cell Biol (2001) 1.83
Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol (1997) 1.66
Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics (2002) 1.57
Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters. J Pharm Sci (2001) 1.48
Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics (2002) 1.34
Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. Am J Hum Genet (1999) 1.21
Role of organic cation transporters in drug absorption and elimination. Annu Rev Pharmacol Toxicol (1998) 1.20
Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther (1998) 1.11
Kinetic and selectivity differences between rodent, rabbit, and human organic cation transporters (OCT1). J Pharmacol Exp Ther (2000) 1.06
Membrane localization of the electrogenic cation transporter rOCT1 in rat liver. Biochem Biophys Res Commun (1998) 0.99
Localization of GFP-tagged concentrative nucleoside transporters in a renal polarized epithelial cell line. Am J Physiol Renal Physiol (2001) 0.89
Cell membrane transport of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the liver and systemic bioavailability. Biochem Biophys Res Commun (2001) 0.83
UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem (2004) 112.47
Membrane transporters in drug development. Nat Rev Drug Discov (2010) 8.56
Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci U S A (2003) 5.77
Visualizing density maps with UCSF Chimera. J Struct Biol (2006) 5.75
BayGenomics: a resource of insertional mutations in mouse embryonic stem cells. Nucleic Acids Res (2003) 4.83
MODBASE, a database of annotated comparative protein structure models, and associated resources. Nucleic Acids Res (2004) 4.54
Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest (2007) 4.47
Development and implementation of high-throughput SNP genotyping in barley. BMC Genomics (2009) 4.23
A genome-wide RNAi screen reveals determinants of human embryonic stem cell identity. Nature (2010) 3.84
Magnitude and distribution of linkage disequilibrium in population isolates and implications for genome-wide association studies. Nat Genet (2006) 3.54
The International Gene Trap Consortium Website: a portal to all publicly available gene trap cell lines in mouse. Nucleic Acids Res (2006) 3.40
Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A (2002) 3.28
Designed divergent evolution of enzyme function. Nature (2006) 3.09
Using sequence similarity networks for visualization of relationships across diverse protein superfamilies. PLoS One (2009) 3.03
ModBase, a database of annotated comparative protein structure models, and associated resources. Nucleic Acids Res (2010) 2.96
Polo-like kinase Cdc5 promotes chiasmata formation and cosegregation of sister centromeres at meiosis I. Nat Cell Biol (2003) 2.94
Unique and redundant roles for HOG MAPK pathway components as revealed by whole-genome expression analysis. Mol Biol Cell (2003) 2.92
The nuclear receptor Nr5a2 can replace Oct4 in the reprogramming of murine somatic cells to pluripotent cells. Cell Stem Cell (2010) 2.89
Control of landmark events in meiosis by the CDK Cdc28 and the meiosis-specific kinase Ime2. Genes Dev (2003) 2.79
Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood (2003) 2.76
Leveraging enzyme structure-function relationships for functional inference and experimental design: the structure-function linkage database. Biochemistry (2006) 2.65
clusterMaker: a multi-algorithm clustering plugin for Cytoscape. BMC Bioinformatics (2011) 2.56
Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res (2011) 2.52
Yeast go the whole HOG for the hyperosmotic response. Trends Genet (2002) 2.45
Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664. Proc Natl Acad Sci U S A (2006) 2.45
Genome-wide association of lipid-lowering response to statins in combined study populations. PLoS One (2010) 2.43
Tools for integrated sequence-structure analysis with UCSF Chimera. BMC Bioinformatics (2006) 2.38
Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res (2006) 2.37
Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancer. Sci Transl Med (2013) 2.34
Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov (2007) 2.32
Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol (2009) 2.20
Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. Pharm Res (2012) 2.18
Software extensions to UCSF chimera for interactive visualization of large molecular assemblies. Structure (2005) 2.12
Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril (2002) 2.10
Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. Sci Transl Med (2011) 2.10
UCSF Chimera, MODELLER, and IMP: an integrated modeling system. J Struct Biol (2011) 2.10
The concentrative nucleoside transporter family, SLC28. Pflugers Arch (2003) 2.06
Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci U S A (2011) 1.98
Pharmacogenomics: challenges and opportunities. Ann Intern Med (2006) 1.96
Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J Immunol (2009) 1.93
Developing predictive molecular maps of human disease through community-based modeling. Nat Genet (2012) 1.88
Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics (2003) 1.79
Weighted gene co-expression network analysis of the peripheral blood from Amyotrophic Lateral Sclerosis patients. BMC Genomics (2009) 1.72
Anatomy and dynamics of DNA replication fork movement in yeast telomeric regions. Mol Cell Biol (2004) 1.69
Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation (2008) 1.68
The Khd1 protein, which has three KH RNA-binding motifs, is required for proper localization of ASH1 mRNA in yeast. EMBO J (2002) 1.62
cis-Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects. Proc Natl Acad Sci U S A (2008) 1.62
A third osmosensing branch in Saccharomyces cerevisiae requires the Msb2 protein and functions in parallel with the Sho1 branch. Mol Cell Biol (2002) 1.58
Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics (2002) 1.57
RHOA is a modulator of the cholesterol-lowering effects of statin. PLoS Genet (2012) 1.54
Genomic dissection of the cell-type-specification circuit in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A (2004) 1.52
Calcium precursors for the production of CaO sorbents for multicycle CO2 capture. Environ Sci Technol (2010) 1.52
The Structure-Function Linkage Database. Nucleic Acids Res (2013) 1.50
Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin. Pharmacogenet Genomics (2010) 1.48
Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. J Pharm Sci (2006) 1.48
Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc Natl Acad Sci U S A (2008) 1.47
Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet Genomics (2009) 1.46